2,5-anhydro-3-O-(α-L-idopyranosyl)-D-mannitol | 99435-36-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,5-anhydro-3-O-(α-L-idopyranosyl)-D-mannitol
• 英文别名: (2S,3R,4S,5S,6S)-2-[(2R,3S,4R,5R)-4-hydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 99435-36-6
• 化学式: C₁₂H₂₂O₁₀
• 分子量: 326.301
• InChiKey: GJWZUOOUQNJKQC-WELRSGGNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  169
• 氢给体数：
  7
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  2,5-anhydro-3-O-(α-L-idopyranosyl)-D-mannitol 在 三氧化硫 、 potassium acetate 、 氢氧化钾 、 strontium(II) acetate 作用下， 以 N,N-二甲基甲酰胺 、 甲醇 、 乙醇 、 水 为溶剂， 以89%的产率得到2,5-anhydro-1,4,6-tri-O-sulfato-3-O-(2,3,4,6-tetra-O-sulfato-α-L-idopyranosyl)-D-mannitol hepta potassium salt
  参考文献：
  名称：

  Synthesis of poly-O-sulfated glycosides of 2,5-anhydro-d-mannitol

  摘要：

  2,5-Anhydro-3-O-beta-D-glucopyranosyl-; -3-O-alpha-D-idopyranosyl-; -3-O-alpha-D-arabinopyranosyl-; -3-O-alpha-L-arabinopyranosyl--; -3-0-beta-D-maltopyranosyl-; -3-O-beta-D-gentiobiopyranosyl-; -1,6-di-O-beta-D-glucopyranosyl-; -1,6-di-O-alpha-L-idopyranosyl,-; -1-O-beta-D-maltopyranosyl-.- -1,3,.6-tri-O-beta-D-glucopyranosyl-; -1,6-di-O-beta-maltopyranosyl- and -1,6-di-O-beta-D-gentiobiopyranosyl-2,5-anhydro-D-mannitol as well as their poly-O-sulfated derivatives were synthesized. The IP3-IC50 values of their sodium and/or potassium salts were determined for structure-activity studies aiming at the synthesis of new, orally active antiasthmatic compounds. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2005.05.006
• 作为产物：
  描述：

  3-O-(2-O-acetyl-α-L-idopyranosyl)-2,5-anhydro-1,6-di-O-benzoyl-D-mannitol 在 sodium methylate 作用下， 以 甲醇 为溶剂， 以82%的产率得到2,5-anhydro-3-O-(α-L-idopyranosyl)-D-mannitol
  参考文献：
  名称：

  Synthesis of poly-O-sulfated glycosides of 2,5-anhydro-d-mannitol

  摘要：

  2,5-Anhydro-3-O-beta-D-glucopyranosyl-; -3-O-alpha-D-idopyranosyl-; -3-O-alpha-D-arabinopyranosyl-; -3-O-alpha-L-arabinopyranosyl--; -3-0-beta-D-maltopyranosyl-; -3-O-beta-D-gentiobiopyranosyl-; -1,6-di-O-beta-D-glucopyranosyl-; -1,6-di-O-alpha-L-idopyranosyl,-; -1-O-beta-D-maltopyranosyl-.- -1,3,.6-tri-O-beta-D-glucopyranosyl-; -1,6-di-O-beta-maltopyranosyl- and -1,6-di-O-beta-D-gentiobiopyranosyl-2,5-anhydro-D-mannitol as well as their poly-O-sulfated derivatives were synthesized. The IP3-IC50 values of their sodium and/or potassium salts were determined for structure-activity studies aiming at the synthesis of new, orally active antiasthmatic compounds. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2005.05.006

文献信息

• [EN] PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY<br/>[FR] DISACCHARIDES HEPTASULFATÉS PURS À BIODISPONIBILITÉ ORALE AMÉLIORÉE
  申请人：OPKO PHARMACEUTICALS LLC

  公开号：WO2018035050A1

  公开（公告）日：2018-02-22

  Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.

  披露了具有用于哮喘或哮喘相关障碍的用途的过硫酸盐双糖。经口服给药的七硫酸盐双糖与静脉给药剂型的生物利用度相当。
• Glycosides and Salts Thereof
  申请人：Kuszmann Janos

  公开号：US20080249165A1

  公开（公告）日：2008-10-09

  The invention relates to new polysulfated glycosides of formula (I), the salts thereof formed with alkali metals or alkaline-earth metals, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

  该发明涉及公式（I）的新多硫酸基糖苷，以及与碱金属或碱土金属形成的盐，以及含有这些化合物作为活性成分的药物组合物。此外，该发明提供了一种预防、治疗或缓解哺乳动物呼吸道急性和慢性炎症性疾病症状的方法，包括哮喘和与哮喘相关的病理学。
• Pure heptasulfated disaccharides having improved oral bioavailability
  申请人：OPKO Pharmaceuticals, LLC.

  公开号：US10829509B2

  公开（公告）日：2020-11-10

  Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.

  本研究公开了可用于治疗哮喘或哮喘相关疾病的七硫化二糖。口服七硫化二糖的生物利用度与静脉注射剂型相当。
• PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY
  申请人：OPKO Pham-iaceutica!s, LLC.

  公开号：US20190185503A1

  公开（公告）日：2019-06-20

  Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.